# RVU120

Source: https://onco.cc/drugs/rvu120/  
OnCo record `rvu120` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.

## Summary

RVU120 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ryvu Therapeutics SA, in acute myeloid leukaemia. Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: SEL120
- Tags: pipeline; ctgov-ingest; registry-only
- Code: RVU120
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of RVU120: https://clinicaltrials.gov/search?intr=RVU120

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- companies: [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/)
- trials: [Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML](https://onco.cc/trials/nct06191263/)

---
JSON: https://onco.cc/api/v1/entities/rvu120.json